DelveInsight’s, “Retinal Vein Occlusion Pipeline Insight, 2023,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Retinal Vein Occlusion pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Retinal Vein Occlusion Emerging drugs, the Retinal Vein Occlusion pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Retinal Vein Occlusion pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Retinal Vein Occlusion Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Retinal Vein Occlusion clinical trials studies, Retinal Vein Occlusion NDA approvals (if any), and product development activities comprising the technology, Retinal Vein Occlusion collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Retinal Vein Occlusion Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Retinal Vein Occlusion Pipeline landscape @ Retinal Vein Occlusion Pipeline Outlook Report
Retinal Vein Occlusion Overview
Retinal vein occlusion (RVO) is the second most common retinal vascular disease and is a common loss of vision in older patients. There are two types of RVO: Branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). Central retinal vein occlusion is an occlusion of the main retinal vein posterior to the lamina cribrosa of the optic nerve and is typically caused by thrombosis. Central retinal vein occlusion is further divided into two categories: non-ischemic (perfused) and ischemic (nonperfused). Non-ischemic CRVO is the most common, accounting for about 70% of cases. A primary risk factor for the development of central retinal vein occlusion is age, with 90% of patients older than 50 years old.
Recent Developmental Activities in the Retinal Vein Occlusion Treatment Landscape
For further information, refer to the detailed Retinal Vein Occlusion Drugs Launch, Retinal Vein Occlusion Developmental Activities, and Retinal Vein Occlusion News, click here for Retinal Vein Occlusion Ongoing Clinical Trial Analysis
Retinal Vein Occlusion Emerging Drugs Profile
The therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every two months or longer treatment regimen.
601A is a recombinant humanized anti-VEGF monoclonal antibody for injection. The proposed main indications are age-related macular degeneration and diabetic macular edema and retinal vein occlusion; and it is currently in Phase II clinical trials.
IBE-814 is designed to deliver a low, consistent, efficacious dose for approximately six to nine months. The goal is to extend clinical benefit while decreasing common steroid-induced adverse events. RIPPLE-1 is a phase II, multi-center, single-masked dose-ranging study designed to evaluate the safety and efficacy of two dosage regimens of IBE-814 IVT in patients with diabetic macular edema (DME) or macular edema due to retinal vein occlusion (RVO).
Retinal Vein Occlusion Pipeline Therapeutics Assessment
There are approx. 15+ key companies which are developing the therapies for Retinal Vein Occlusion. The companies which have their Retinal Vein Occlusion drug candidates in the mid to advanced stage, i.e. Phase III include, Kodiak sciences
Find out more about the Retinal Vein Occlusion Pipeline Segmentation, Therapeutics Assessment, Retinal Vein Occlusion Emerging Drugs @ Retinal Vein Occlusion Treatment Landscape
Scope of the Retinal Vein Occlusion Pipeline Report
Table of Content
Got Queries? Find out the related information on Retinal Vein Occlusion Mergers and acquisitions, Retinal Vein Occlusion Licensing Activities @ Retinal Vein Occlusion Recent Trends, and Future Perspectives
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
